




FIG. 1




FIG. 2

3/34





FIG. 3

4/34






FIG. 5

6/34




FIG. 6A

7/34




FIG. 6B






FIG. 7A

9/34



	KLB		FGFR1c		Activity
	GH2	GH1	D3	D2	
F1K_scFv4		22414 22393	ADI-19842		*
F1K_scFv5		22401 22393	ADI-19842		*
F1K_scFv6	22532	22393	ADI-19842		****
REGN4366		22393	ADI-19842		**
REGN4304	REGN4304			REGN4304	***

FIG. 7B



2+1 N-scFv Configuration Variants




FIG. 8B




FIG. 9

14/34




FIG. 10B




FIG. 11A




FIG. 11B

17/34




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 13A

20/34





FIG. 13B




FIG. 13C

22/34




FIG. 13D




FIG. 14




FIG. 15

10	20	30	40	50	60
ASTKGPSVFP	LAPCSRSTSE	STAALGCLVK	DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS
← CH1 Hinge → CH2 →					
70	80	90	100	110	120
GLYSLSSVVT	VPSSSLGTKT	YTCNVVDHKPS	NTKVDKRVES	KYGPHCPSCP	APEFLGGPSV
Upper Core Lower					
Hinge Hinge Hinge					
130	140	150	160	170	180
FLFPPKPKDT	LMISRTPEVT	CVVVDVSOED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTY
CH3 →					
190	200	210	220	230	240
RVSVLTVLH	QDWLNGKEYK	CKVSNKGLPS	SIEKTISKAK	GQPREPQVYT	LPQSQEEMTK
250	260	270	280	290	300
NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPVLDS	DGSFFLYSRL	TVDKSRWQEG
310	320				
NVFSCSVMHE	ALHNHYTQKS	LSLSLGK			

FIG. 16

	Upper Hinge	Core Hinge				Lower Hinge								CH2	CH3	Hinge SEQ ID NO:	
		226	227	228	229	230	231	232	233	234	235	236	237	238			
Construct	216-225 (IgG1)														CH2	CH3	
hIgG1 PVA	EPKSCDKTHT	C	P	P	C	P	A	P	P	V	A	-	G	P	IgG1	IgG1	66
hIgG1s	EPKSCDKTHT	C	P	P	C	P	A	P	P	V	A	-	G	P	IgG4	IgG1	67
hIgG1	EPKSCDKTHT	C	P	P	C	P	A	P	E	L	L	G	G	P	IgG1	IgG1	68
hIgG2	ERK CCVE	C	P	P	C	P	A	P	P	V	A	-	G	P	IgG2	IgG2	69
hIgG4 S108P	ESKYGPP	C	P	P	C	P	A	P	E	F	L	G	G	P	IgG4	IgG4	70
hIgG4s	ESKYGPP	C	P	P	C	P	A	P	P	V	A	-	G	P	IgG4	IgG4	71
hIgG4	ESKYGPP	C	P	S	C	P	A	P	E	F	L	G	G	P	IgG4	IgG4	72

FIG. 17




FIG. 18

28/34




FIG. 19A




FIG. 19B

29/34




FIG. 19C




FIG. 19D

30/34




FIG. 19E




FIG. 19F

31/34




FIG. 19G

32/34

Surrogate ADCC Assay of scFv based Alternative Format Antibodies




FIG. 20

Surrogate ADCC Assay of Fab based Alternative Format Antibodies




FIG. 21

33/34

HEK293.SREluc.hFGFR1c.hKLB Reporter Assay
Activity of scFv Based Alternative Format Antibodies




FIG. 22

HEK293.SREluc.hFGFR1c.hKLB Reporter Assay
Activity of Fab Based Alternative Format Antibodies





FIG. 23

34/34



	EC50 (M)	%Activity of FGF21
● His.hFGF21	1.4E-10	100.0
○ F1k_scFv6-LK30, IgG1 PVA	1.4E-10	95.2
■ F1k_Fab6-LK15, IgG1 PVA	4.3E-10	50.7
□ F1k_scFv6-LK30, IgG4 S108P	1.6E-10	62.2
▲ F1k_Fab6-LK15, IgG4 S108P	5.1E-10	41.1

FIG. 24